Cutaneous sıde-effects of the potential COVID-19 drugs.
Identifieur interne : 001445 ( Main/Exploration ); précédent : 001444; suivant : 001446Cutaneous sıde-effects of the potential COVID-19 drugs.
Auteurs : Ümit Türsen [Turquie] ; Belma Türsen [Turquie] ; Torello Lotti [Italie]Source :
- Dermatologic therapy [ 1529-8019 ] ; 2020.
Descripteurs français
- KwdFr :
- Antiviraux (effets indésirables), Antiviraux (usage thérapeutique), Betacoronavirus (MeSH), Effets secondaires indésirables des médicaments (épidémiologie), Humains (MeSH), Incidence (MeSH), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Maladies de la peau (induit chimiquement), Maladies de la peau (épidémiologie), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Santé mondiale (MeSH).
- MESH :
- effets indésirables : Antiviraux.
- induit chimiquement : Maladies de la peau.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antiviraux.
- épidémiologie : Effets secondaires indésirables des médicaments, Infections à coronavirus, Maladies de la peau, Pneumopathie virale.
- Betacoronavirus, Humains, Incidence, Pandémies, Santé mondiale.
English descriptors
- KwdEn :
- Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Drug-Related Side Effects and Adverse Reactions (epidemiology), Global Health (MeSH), Humans (MeSH), Incidence (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), SARS-CoV-2 (MeSH), Skin Diseases (chemically induced), Skin Diseases (epidemiology).
- MESH :
- chemical , adverse effects : Antiviral Agents.
- chemical , therapeutic use : Antiviral Agents.
- chemically induced : Skin Diseases.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Drug-Related Side Effects and Adverse Reactions, Pneumonia, Viral, Skin Diseases.
- Betacoronavirus, COVID-19, Global Health, Humans, Incidence, Pandemics, SARS-CoV-2.
Abstract
COVID-19 disease is a highly contagious and particularly popular problem in all countries. A variety of repurposed drugs and investigational drugs such as remdesivir, chloroquine, hydroxychloroquine, ritonavir, lopinavir, interferon-beta, and other potential drugs have been studied for COVID19 treatment. We reviewed the potential dermatological side-effects of these drugs.
DOI: 10.1111/dth.13476
PubMed: 32358890
PubMed Central: PMC7262017
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cutaneous sıde-effects of the potential COVID-19 drugs.</title>
<author><name sortKey="Tursen, Umit" sort="Tursen, Umit" uniqKey="Tursen U" first="Ümit" last="Türsen">Ümit Türsen</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, School of Medicine, Mersin University, Mersin, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Dermatology, School of Medicine, Mersin University, Mersin</wicri:regionArea>
<wicri:noRegion>Mersin</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tursen, Belma" sort="Tursen, Belma" uniqKey="Tursen B" first="Belma" last="Türsen">Belma Türsen</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Health Science, Toros University, Mersin, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Health Science, Toros University, Mersin</wicri:regionArea>
<wicri:noRegion>Mersin</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lotti, Torello" sort="Lotti, Torello" uniqKey="Lotti T" first="Torello" last="Lotti">Torello Lotti</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, School of Medicine, Marconi University, Rome, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Dermatology, School of Medicine, Marconi University, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32358890</idno>
<idno type="pmid">32358890</idno>
<idno type="doi">10.1111/dth.13476</idno>
<idno type="pmc">PMC7262017</idno>
<idno type="wicri:Area/Main/Corpus">001817</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001817</idno>
<idno type="wicri:Area/Main/Curation">001817</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001817</idno>
<idno type="wicri:Area/Main/Exploration">001817</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cutaneous sıde-effects of the potential COVID-19 drugs.</title>
<author><name sortKey="Tursen, Umit" sort="Tursen, Umit" uniqKey="Tursen U" first="Ümit" last="Türsen">Ümit Türsen</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, School of Medicine, Mersin University, Mersin, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Dermatology, School of Medicine, Mersin University, Mersin</wicri:regionArea>
<wicri:noRegion>Mersin</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tursen, Belma" sort="Tursen, Belma" uniqKey="Tursen B" first="Belma" last="Türsen">Belma Türsen</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Health Science, Toros University, Mersin, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Health Science, Toros University, Mersin</wicri:regionArea>
<wicri:noRegion>Mersin</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lotti, Torello" sort="Lotti, Torello" uniqKey="Lotti T" first="Torello" last="Lotti">Torello Lotti</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, School of Medicine, Marconi University, Rome, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Dermatology, School of Medicine, Marconi University, Rome</wicri:regionArea>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Dermatologic therapy</title>
<idno type="eISSN">1529-8019</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (adverse effects)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Drug-Related Side Effects and Adverse Reactions (epidemiology)</term>
<term>Global Health (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Incidence (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Skin Diseases (chemically induced)</term>
<term>Skin Diseases (epidemiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (effets indésirables)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Effets secondaires indésirables des médicaments (épidémiologie)</term>
<term>Humains (MeSH)</term>
<term>Incidence (MeSH)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Maladies de la peau (induit chimiquement)</term>
<term>Maladies de la peau (épidémiologie)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Santé mondiale (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Skin Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Pneumonia, Viral</term>
<term>Skin Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Maladies de la peau</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term>
<term>Infections à coronavirus</term>
<term>Maladies de la peau</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Global Health</term>
<term>Humans</term>
<term>Incidence</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term>
<term>Humains</term>
<term>Incidence</term>
<term>Pandémies</term>
<term>Santé mondiale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">COVID-19 disease is a highly contagious and particularly popular problem in all countries. A variety of repurposed drugs and investigational drugs such as remdesivir, chloroquine, hydroxychloroquine, ritonavir, lopinavir, interferon-beta, and other potential drugs have been studied for COVID19 treatment. We reviewed the potential dermatological side-effects of these drugs.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32358890</PMID>
<DateCompleted><Year>2020</Year>
<Month>11</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-8019</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>33</Volume>
<Issue>4</Issue>
<PubDate><Year>2020</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Dermatologic therapy</Title>
<ISOAbbreviation>Dermatol Ther</ISOAbbreviation>
</Journal>
<ArticleTitle>Cutaneous sıde-effects of the potential COVID-19 drugs.</ArticleTitle>
<Pagination><MedlinePgn>e13476</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/dth.13476</ELocationID>
<Abstract><AbstractText>COVID-19 disease is a highly contagious and particularly popular problem in all countries. A variety of repurposed drugs and investigational drugs such as remdesivir, chloroquine, hydroxychloroquine, ritonavir, lopinavir, interferon-beta, and other potential drugs have been studied for COVID19 treatment. We reviewed the potential dermatological side-effects of these drugs.</AbstractText>
<CopyrightInformation>© 2020 Wiley Periodicals LLC.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Türsen</LastName>
<ForeName>Ümit</ForeName>
<Initials>Ü</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-5807-6759</Identifier>
<AffiliationInfo><Affiliation>Department of Dermatology, School of Medicine, Mersin University, Mersin, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Türsen</LastName>
<ForeName>Belma</ForeName>
<Initials>B</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0003-4735-0705</Identifier>
<AffiliationInfo><Affiliation>Department of Health Science, Toros University, Mersin, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lotti</LastName>
<ForeName>Torello</ForeName>
<Initials>T</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0003-0840-1936</Identifier>
<AffiliationInfo><Affiliation>Department of Dermatology, School of Medicine, Marconi University, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Dermatol Ther</MedlineTA>
<NlmUniqueID>9700070</NlmUniqueID>
<ISSNLinking>1396-0296</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012871" MajorTopicYN="N">Skin Diseases</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">dermatology</Keyword>
<Keyword MajorTopicYN="N">side-effects</Keyword>
<Keyword MajorTopicYN="N">skin</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>11</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32358890</ArticleId>
<ArticleId IdType="doi">10.1111/dth.13476</ArticleId>
<ArticleId IdType="pmc">PMC7262017</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Australas J Dermatol. 2018 Aug;59(3):e168-e174</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29411351</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dermatol Ther. 2020 Jul;33(4):e13476</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32358890</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Immunol. 2014;121:191-211</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24388216</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Eur Acad Dermatol Venereol. 2020 May;34(5):e212-e213</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32215952</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2015 Apr 28;(4):CD003262</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25919144</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Life Sci. 2020 Jun 15;251:117627</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32251634</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Mol Sci. 2020 Apr 10;21(7):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32290293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mediterr J Rheumatol. 2019 Sep 30;30(3):177-185</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32185362</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Ann. 2020 Mar 1;49(3):e132-e139</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32155279</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Cancer. 2016 Jun;60:12-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27043866</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2018 Sep 06;9:CD001127</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30187450</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Cutan Pathol. 2006 Apr;33(4):309-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16630182</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Cent Sci. 2020 Mar 25;6(3):315-331</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32226821</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Medicine (Baltimore). 2019 May;98(19):e15553</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31083216</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):e30-e31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32032529</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cutan Ocul Toxicol. 2017 Jun;36(2):199-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27345420</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Negl Trop Dis. 2012;6(6):e1685</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22679525</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Case Rep Dermatol. 2019 Nov 27;11(3):317-321</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31911769</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Dermatol Venereol. 2016 May;143(5):336-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27161648</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105967</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32259575</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Med Res. 2018 Jun;16(1-2):41-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29610119</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rheumatology (Oxford). 2016 Aug;55(8):1499-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27143789</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Indian Dermatol Online J. 2019 Aug 28;10(5):503-518</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31544068</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32258207</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2020 Jan;25(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32019669</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2002 Dec;46(12):3392-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12483751</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Dermatol. 2001 Jul;40(7):427-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11678994</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ecancermedicalscience. 2020 Mar 27;14:1022</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32256705</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Indian J Pharmacol. 2016 Jan-Feb;48(1):83-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26997729</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Mol Sci. 2020 Mar 25;21(7):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32218340</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dermatol Ther. 2018 Sep;31(5):e12679</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30230152</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Acad Dermatol. 2010 Oct;63(4):549-61; quiz 561-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20846563</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Indian J Dermatol Venereol Leprol. 2008 May-Jun;74(3):234-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18583790</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mil Med Res. 2020 Feb 6;7(1):4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32029004</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Med. 2016 Feb;44(2):275-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26584195</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e250-e251</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32294264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ Case Rep. 2011 Aug 04;2011:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22687684</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rheumatology (Oxford). 2019 Nov 1;58(Suppl 6):vi9-vi22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31769856</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Crit Care Med. 2016 Sep 15;194(6):701-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27014936</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Drugs Dermatol. 2017 Jul 1;16(7):714-716</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28697228</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Case Rep Intern Med. 2019 Dec 19;7(1):001383</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32015973</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chemother. 2017 Dec;29(6):380-382</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27741937</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neurology. 1996 Sep;47(3):674-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8797463</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Case Rep Dermatol. 2014 May 17;6(2):145-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24932169</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Italie</li>
<li>Turquie</li>
</country>
<region><li>Latium</li>
</region>
<settlement><li>Rome</li>
</settlement>
</list>
<tree><country name="Turquie"><noRegion><name sortKey="Tursen, Umit" sort="Tursen, Umit" uniqKey="Tursen U" first="Ümit" last="Türsen">Ümit Türsen</name>
</noRegion>
<name sortKey="Tursen, Belma" sort="Tursen, Belma" uniqKey="Tursen B" first="Belma" last="Türsen">Belma Türsen</name>
</country>
<country name="Italie"><region name="Latium"><name sortKey="Lotti, Torello" sort="Lotti, Torello" uniqKey="Lotti T" first="Torello" last="Lotti">Torello Lotti</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001445 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001445 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:32358890 |texte= Cutaneous sıde-effects of the potential COVID-19 drugs. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32358890" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
This area was generated with Dilib version V0.6.38. |